Advertisement

Journal of Endocrinological Investigation

, Volume 19, Issue 1, pp 30–34 | Cite as

Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test

  • Zvonimir Lević
  • D. Micić
  • J. Nikolić
  • N. Stojisavljević
  • D. Sokić
  • S. Janković
  • A. Kendereški
  • M. Mavra
Article

Abstract

Ten patients in acute exacerbation of multiple sclerosis were treated with 1000 mg of methylprednisolone for 7 days, followed by abrupt cessation of therapy. The function of hypothalamic-pituitary-adrenal (HPA) axis was assessed by the response of ACTH and Cortisol to insulin tolerance test (ITT). ITT was performed 1 day before and 1, 3, 8, 13 and 23 days after the termination of the therapy (days 0, 8, 10, 15, 20 and 30 of the study, respectively). The response of these hormones to insulin-induced hypoglycemia prior to therapy was normal. There was no suppression of the ACTH response to hypoglycemia after the methylprednisolone therapy based on the 100% rise of ACTH after ITT. Cortisol response during ITT was suppressed at day 8 (1 day after ending of therapy) but recovered on day 10 (3 days after ending of therapy). In conclusion, 7 day-therapy with 1000 mg methylprednisolone does not result in the permanent suppression of the HPA axis, suggesting that no regular supplemental corticosteroid coverage is required. The observed transitory suppression of the HPA axis recovered spontaneously after the therapy.

Key-words

Hypothalamic-pituitary-adrenal axis multiple sclerosis methylprednisolone ACTH Cortisol insulin tolerance test 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Troiano R., Cook S.D., Dowling P.C. Steroid therapy in multiple sclerosis. Point of view. Arch. Neurol. 44: 803, 1987.PubMedCrossRefGoogle Scholar
  2. 2.
    Barnes M.P., Bateman D.E., Cleland P.G., Dick D.J., Walls T.J., Newman P.K. Intravenous methylprednisolone for multiple sclerosis in relapse. J. Neurol. Neurosurg. Psychiatr. 48: 157, 1985.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Durelli L., Cocito D., Riccio A., Barile C., Bergamasco B., Baggio G.F., Perla F., Delsedime M., Gusmaroli G., Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlation. Neurology 36: 238, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Streeten D.H.P., Anderson G.H., Dalakos T.G., Seeley D., Mallov J.S., Eusebio R., Sunderlin F.S., Badawy S.Z.A., King R.B. Normal and abnormal function of the hypothalamic-pituitary-adrenocortical system in man. Endocr. Rev. 5: 371, 1984.PubMedCrossRefGoogle Scholar
  5. 5.
    Lević Z., Mavra M., Manojlović D., Nikolić J., Subotić N. Cortisol and ACTH levels in plasma of MS patients treated with high-dose methylprednisolone intravenously. In: Meyer-Rienecker H., Olischer R.M. (Eds.), Actual aspects of multiple sclerosis. Progress in MS research. Rostock, Wilchelm-Pieck-Universitat, 1988, p. 123.Google Scholar
  6. 6.
    Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis. Guidelines for research protocol. Ann. Neurol. 13: 227, 1983.PubMedCrossRefGoogle Scholar
  7. 7.
    Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology (Cleveland) 33: 1444, 1983.CrossRefGoogle Scholar
  8. 8.
    Wass J.A.H., Besser G.M. Tests of pituitary function. In: De Groot L.J. (Ed.), Endocrinology. W.B. Saunders Company, Philadelphia, 1989, p. 492.Google Scholar
  9. 9.
    Orth D.N., Kovacs W.J., DeBold C.R. The adrenal cortex. In: Wilson J.D., Foster D.W. (Eds.), William’s Textbook of Endocrinology. W.B. Saunders Company, Philadelphia, 1992, p. 489.Google Scholar
  10. 10.
    Swartz S.L., Dluhy R.G. Corticosteroids: Clinical pharmacology and therapeutic use. Drugs 16: 238, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Miro J., Amado J.A., Pesquera C., Lopez-Cordovilla J.J., Berciano J. Assessment of the hypothalamic-pituitary-adrenal axis function after corticosteroid therapy for MS relapses. Acta Neurol. Scand. 81: 534, 1990.CrossRefGoogle Scholar
  12. 12.
    Trotter J.L., Garvey W.F. Prolonged effects of large dose methylprednisolone infusion in multiple sclerosis. Neurology 30: 702, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1996

Authors and Affiliations

  • Zvonimir Lević
    • 1
  • D. Micić
    • 2
  • J. Nikolić
    • 1
  • N. Stojisavljević
    • 1
  • D. Sokić
    • 1
  • S. Janković
    • 1
  • A. Kendereški
    • 2
  • M. Mavra
    • 1
  1. 1.Institute of NeurologyClinical Center of Serbia, BelgradeBelgradeYugoslavia
  2. 2.Institute of EndocrinologyClinical Center of SerbiaBelgradeYugoslavia

Personalised recommendations